Open Access Open Badges Research article

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

David R Strutton1, Raymond A Farkouh1*, Jaime L Rubin2, Lisa J McGarry2, Paul M Loiacono1, Keith P Klugman3, Steven I Pelton4, Kristen E Gilmore2 and Milton C Weinstein5

Author Affiliations

1 Vaccines Market Access and Outcomes Research Specialty Care Business Unit, Pfizer Inc, 500 Arcola Road, Dock D, COL-D4555, Collegeville, PA 19426-3930, USA

2 OptumInsight, 10 Cabot Road, Suite 304, Medford, MA, 02155, USA

3 Hubert Department of Global Health, Rollins School of Public Health, Emory University, 1518 Clifton Road, N.E – CNR Building Room 6009, Atlanta, GA, 30322, USA

4 Boston University School of Medicine, 670 Albany Street, Boston, MA, 02118, USA

5 Department of Health Policy and Management, Harvard School of Public Health, Harvard University, 718 Huntington Avenue, Boston, MA, 02115, USA

For all author emails, please log on.

BMC Infectious Diseases 2012, 12:175  doi:10.1186/1471-2334-12-175

Published: 3 August 2012



Analysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort would ever receive the catch-up vaccination; a previous analysis assumed 87%.


This updated figure was applied to a previously published 10-year Markov model while holding all other inputs constant.


Our model estimated that the catch-up program as currently implemented is estimated to prevent an additional 1.7 million cases of disease in children aged ≤59 months over a 10-year period, compared with routine PCV13 vaccination with no catch-up program.


Because 39% catch-up uptake is less than the level of completion of the 4-dose primary PCV13 series, vaccine-preventable cases of pneumococcal disease and related deaths could be decreased further with additional uptake of catch-up vaccination in the catch-up eligible cohort.

Pneumococcal conjugate vaccine; Catch-up vaccination; Pneumococcal; PCV13; 13-valent